• About
  • Meet The Team
  • Privacy Policy
Friday, March 5, 2021

Stocks Telegraph
  • Login
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers
No Result
View All Result
Stocks Telegraph
No Result
View All Result

Fluidigm (FLDM) Stock Gives Green Signal as it obtains CE-IVD ‎Mark for Its COVID-19 Test

by Ali Hassan
January 22, 2021
in Featured
Share on FacebookShare on Twitter

The biotech firm has made a notable development for its COVID-19 test. While the stock soars as FLDM nears the anticipated results for the full year 2020.

Fluidigm Corp. (FLDM) stock is on a roll in pre-session today following a bullish end to the trading on Thursday. As we write this, FLDM stock had soared up to 26%. The company’s full-year 2020 results are near disclosure and are anticipated to score well overall. The bulls are eyeing the stock as we near the yearly report.

Moreover, the biotech company just announced that it has obtained the CE-IVD mark for its Advanta™ Dx SARS-CoV-2 RT-PCR Assay. This is a great achievement for Fluidigm as its Advanta testing for COVID-19 comes up with a unique technology—that gives convenient results for SARS-Cov-2 virus testing.

What’s Next?

Fluidigm Corp. (FLDM)is a hands-on biotech tool provider that focuses on improving patient’s life through comprehensive health insight. Fluidigm stock is making progress along with the developments happening around, which is good. But how’s the stock getting backed by its business operations?

On Jan. 22, the company announced that it received the CE-IVD mark for its Advanta™ for the coronavirus testing. This new testing method is an extraction-free saliva-based test that helps in detecting nucleic acid from the SARS-CoV-2 virus. The following testing method complies with the European Union In Vitro Diagnostic Directive.

The latest Advanta Dx Assay and results from paired nasopharyngeal samples are proved with 100% demonstration during the clinical studies. The Advanta DxAssay does not require collection through the invasive nasopharyngeal swab, which makes it more reliable and convenient.

Moreover, the team of peer-reviewed research is scrutinizing the accuracy of the saliva-basedSARS-CoV-2 test. Based on the results published by JAMA Internal Medicine, the saliva-based tests have shown similar specificity and sensitivity compared to the nasopharyngeal-based collection.

The CEO and President of Chris Linthwaite said that the testing market of COVID-19 is expected to reach up to $5 to 7 billion this year. This is a big plus for the company that will drive more revenue in the coming time.

The company has scheduled to release its Q4 and full-year 2020 results on Feb. 10, 2020. In the last quarter, Fluidigm reported solid quarterly results. The revenue during Q3 soared by 50.4% to $39.9 million year-over-year. General Product & service and Microfluidics product &service revenues increased by 34.4% and 88%, respectively. While other revenue accumulated at around $4.5 million.

Moreover, the GAAP net loss also decreased from $12.9 million to $6 million from the same period in 2019. The non-GAAP income came positive with $2.5 million compared to a loss of $6.2 million in Q3 2019. So, the results have improved significantly over the past year with a hike in health services amid the COVID-19 pandemic.

Conclusion

The Q4 and full-year results are also expected to report increased income and revenues. Moreover, the strengthening test capability of the COVID-19 will help the company to continue strong growth in 2021. So, Fluidigm Corp. (FLDM) has the potential to make big moves this year.

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

Tags: ‎ Fluidigm News‎ Fluidigm StockFLDMFLDM NewsFLDM StockFluidigm

Related Posts

Marinus Pharmaceuticals (NASDAQ: MRNS) Is Popping Today. Here’s Why
Featured

Apple (AAPL) or Alphabet (GOOGL): Which is the Better Stock Pick?

March 1, 2021
ASML Holding (NASDAQ: ASML) Announces 2020 Q3 Results
Featured

What dragged Vistra Corp (VST) about 25% lower?

February 27, 2021
High Flying Plasma Pharmaceuticals as FDA Approves Plasma-based COVID-19 Treatment
Featured

Three Top Coronavirus Stocks to Buy Anytime Soon

February 27, 2021
Tesla Inc. (NASDAQ: TSLA) Reportedly Discuss Nickel Supply Deal With Top Miner BHP
Featured

AMC Entertainment (AMC) Avoids Bankruptcy as Shares Pop Up

January 27, 2021
Top 3 Health Care Stocks that can attract investors in 2021
Featured

Top 3 Health Care Stocks that can attract investors in 2021

January 27, 2021
Sunworks (NASDAQ: SUNW) Stock Is Soaring Today. Here’s Why
Featured

Overstock.com (OSTK) Set to Convert its blockchain-based subsidiary to a limited partnership “Fund”

January 27, 2021
Next Post
Top Performers Markets Awaits News from Congress and the Federal Reserve

GameStop (GME) Stock Continues to Spike Days after the Appointment of Ryan Cohen

GameStop Corp. (GME) Stock has skyrocketed in the Pre-Market: What’s happening?

Top 3 Reasons Why AzurRx Biopharma Inc [AZRX] is Gaining Bullish Momentum
by ST Staff
February 25, 2021
0

GameStop Corp. (GME) shares have been on a skywalk. The videogame platform seller is captivating the attention in the market...

Read more

The Three SPAC Stocks to Buy Anytime Soon

by Ali Hassan
February 26, 2021
0

The SPAC stocks have been in action and there are some potential investment opportunities to watch for. A special purpose...

Read more

Early Morning Vibes: Top 4 Stocks To Buy Right Now

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Hasnain R
March 3, 2021
0

US stock indices closed with growth on Monday. The last week rally in US government bond yields stalled, easing investors'...

Read more

The fundamentals of KemPharm Inc. (KMPH) lend themselves to long-term investors

Why IBIO Inc [IBIO] is the Best Covid-19 Vaccine Stock to Bet On
by Hasnain R
March 3, 2021
0

KemPharm, Inc. (NASDAQ: KMPH)has performed -15.80% so far this year, while over the last seven days it has performed -4.8%....

Read more

Early Morning Vibes: Check These 4 Hot Stocks Right Now

GEVO Inc [GEVO]  – A Top Stock To Watch For The Remainder Of 2020
by Hasnain R
February 26, 2021
0

Yesterday the US indices plunged deep into the red again. The last two days have seen a brave recovery, but panic...

Read more
  • About
  • Meet The Team
  • Privacy Policy

© 2020 Stocks Telegraph - All Rights Reserved

No Result
View All Result
  • Home
  • Featured
  • Investing
  • Morning News
  • Mid Day Movers

© 2020 Stocks Telegraph - All Rights Reserved

Welcome Back!

Login to your account below

Forgotten Password?

Create New Account!

Fill the forms below to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Get The Best Stocks To Trade Every Day!

Join now to get the Stockstelegraph.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

This website uses cookies. By continuing to use this website you are giving consent to cookies being used. Visit our Privacy and Cookie Policy.